Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer Clinical Trial
Official title:
Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer: An Open-label, Single-armed Phase II Trial
The purpose of this study is to evaluate the efficacy and safety of Chidamide with EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
(1)The efficacy of the regimen is evaluated by objective remission rate, disease control
rate, progress free survival, duration of remission, overall survival, time to progression.
Safety is monitored by vital signs, blood routine test, liver function, kidney function and
electrolytes level, ECG, and cardiac ultrasonography.
All the data is documented by CRF form, and carefully preserved.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment